PUNE, India, April 13, 2017 /PRNewswire/ --
The latest pipeline report Heavy Metal Poisoning Pipeline Review, H1 2017, provides an overview of the Heavy Metal Poisoning (Toxicology) pipeline landscape. The pipeline report Heavy Metal Poisoning Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Heavy Metal Poisoning (Toxicology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.
Browse 16 Tables and 10 Figures, 5 Major Company Profiles, spread across 41 pages available at http://www.reportsnreports.com/reports/944656-heavy-metal-poisoning-pipeline-review-h1-2017.html.
Heavy Metal Poisoning Companies Involved in Therapeutics Development are Alnylam Pharmaceuticals Inc, La Jolla Pharmaceutical Company, Medesis Pharma SA, Novartis AG and PDX Pharmaceuticals LLC.
Heavy Metal Poisoning Drug Profiles are ALN-TMP, deferasirox, deferoxamine mesylate, emeramide, LJPC-401, NU-01, NU-02, NU-03, PDX-003.
The report covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Heavy Metal Poisoning (Toxicology) pipeline guide also reviews of key players involved in therapeutic development for Heavy Metal Poisoning and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 1, 4 and 2 respectively. Similarly, the Universities portfolio in Discovery stages comprises 1 molecules, respectively.
Order a Copy of Report at http://www.reportsnreports.com/purchase.aspx?name=944656.
Heavy Metal Poisoning (Toxicology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. The pipeline guide evaluates Heavy Metal Poisoning (Toxicology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. The pipeline guide encapsulates all the dormant and discontinued pipeline projects. The pipeline guide reviews latest news related to pipeline therapeutics for Heavy Metal Poisoning (Toxicology).
- Radiation Injury - Pipeline Review, H1 2017
- Drug Overdose - Pipeline Review, H1 2017
- Chemotherapy Induced Peripheral Neuropathy - Pipeline Review, H1 2017
Explore more reports on Pharmaceuticals Market at http://www.reportsnreports.com/market-research/pharmaceuticals/.
ReportsnReports.com is an online market research reports library of 500,000+ in-depth studies of over 5000 micro markets. Not limited to any one industry, ReportsnReports.com offers research studies on agriculture, energy and power, chemicals, environment, medical devices, healthcare, food and beverages, water, advanced materials and much more.
2nd Floor, Metropole Building,
Next to Inox Theatre,
Bund Garden Road, Pune - 411013.
Connect with Us:
RSS/Feeds: http: //http://www.reportsnreports.com/feed/l-latestreports.xml